drugset / Trial / NCT00407537

Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors

NCT00407537

Phase 4 Completed 1531 enrolled Viatris Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.

Timeline

Start
2007-03
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Amlodipine Other / unclassified 10 mg
Subject Atorvastatin Small molecule 10 mg
Subject Atorvastatin Small molecule 20 mg